Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases.
The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use.
Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product.
Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation.
Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.
The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use.
Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product.
Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation.
Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.
Employees: 11-50
Total raised: $16.73M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Flerie Inv... | flerie.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.12.2021 | - | $5.65M | - |
| 16.10.2019 | - | $11.07M | - |
Mentions in press and media 3
| Date | Title | Description |
| 03.12.2021 | Amarna Therapeutics raises €5M to accelerate its gene therapy towards clinical trials | Amarna Therapeutics, a Leiden-based biotech company, developing curative gene therapies for a range of rare and prevalent diseases, announced that it has secured €5M funding. Of this total funding, €4M was provided by existing investors C4 ... |
| 03.09.2020 | Dutch Amarna Therapeutics Announces the Appointment of Steen Klysner as Chief Executive Officer | |
| 16.10.2019 | Amarna Therapeutics Raises €10M in Funding | Amarna Therapeutics, a Leiden, the Netherlands-based biotechnology company, raised €10m in funding. The round was led by Flerie Invest AB with an innovation credit coming from the “Netherlands Enterprise Agency” (RVO.nl) and existing shareh... |